OBI Pharma, Inc. have appointed Heidi Wang, Ph.D. as Chief Executive Officer, a position previously held by Chairman and CEO, Yun Yen, MD. Dr. Wang brings a wealth of global executive management, scientific knowledge, development, and regulatory experience during her ~30 years tenure at Bristol Myers Squibb company (BMS)™.Prior to joining OBI Pharma, she was Vice President, Head of Global Regulatory Sciences Oncology. Additionally, she has held executive and senior management roles of increasing responsibilities as Interim Head of R&D and Regulatory in China, US and International Regulatory Strategy, Global Product Labeling, Medical Communications, and Research Discovery.

Dr. Wang has received the following degrees: Ph.D. and M.S. degrees at the University of Notre Dame (South Bend, IN) and B.S. degree at Fu-Jen University (Taipei, Taiwan). She also received postdoctoral training in cancer biology at The Cold Spring Harbor Laboratory (Cold Spring Harbor, NY). She has won numerous awards and authored numerous scientific publications during her career.